Mr. Shaun Flanagan:

The HSE, the Department of Public Expenditure and Reform, and the Department of Health were engaged in negotiations around a new framework agreement with the pharmaceutical industry in 2022. I should acknowledge that part of the discussions on that were how both sides could improve the throughput of medicines through the process and how we could find ways to shorten the timelines. We are committed to trying to address some of the issues that came up there. We see somewhat of a change from some companies in how they submit their pricing to us in that they tend to get to the end quicker, as it were, where before we would have had fairly extended negotiations that might have gone on longer than they should have. We get a feeling that at least some companies are getting to the end point quicker, which is helpful for all of us.